Pipeline

Why Gathering Health Economic Data for Cancer Drugs is Now Essential

Why Gathering Health Economic Data for Cancer Drugs is Now Essential

Health economic and outcomes research datasets have rarely been integral to product development and communication plans.

Five things for pharma marketers to know: Friday, January 29, 2016

Five things for pharma marketers to know: Friday, January 29, 2016

By

FDA approves Merck's HCV doublet regimen; Gilead CEO steps down; Clinton takes aim at Valeant price hikes

Top 25 metabolic products, 2014-2015

Sanofi is the category leader. Its product, Lantus Solostar, brought in $5.27 billion in US sales between October 2014 and September 2015.

Diabetes R&D narrows in on glycemic control

Diabetes R&D narrows in on glycemic control

By

New entrants in the type 2 diabetes treatment market share a similar goal: To solve patients' constant struggle with glycemic control.

Marketing challenges remain in crowded metabolic market

Marketing challenges remain in crowded metabolic market

By

Experts insist that R&D efforts in the category must mirror educational campaigns and lifestyle changes, and quickly.

Five things for pharma marketers to know: Friday, January 22, 2016

Five things for pharma marketers to know: Friday, January 22, 2016

By

NICE recommends Opdivo for skin cancer; Sanofi layoffs could be looming; Senators ask for feedback on Sovaldi investigation

Five things for pharma marketers to know: Wednesday, January 13, 2016

Five things for pharma marketers to know: Wednesday, January 13, 2016

By

Biden to lead "moonshot" to cure cancer; Pfizer/Allergan merger to create "best pipeline in the industry," CEO says; AMA invests in health tech startup

New multiple myeloma drugs prompt cost-effectiveness report

New multiple myeloma drugs prompt cost-effectiveness report

By

The FDA in November approved three new drugs that treat the rare blood cancer.

Five things for pharma marketers to know: Friday, January 8, 2016

Five things for pharma marketers to know: Friday, January 8, 2016

By

GSK will stop using outside doctors to promote its drugs; Roche will file its immuno-oncology drug for approval; Mylan inks deal to develop six biosimilars

Five things for pharma marketers to know: Tuesday, January 5, 2016

Five things for pharma marketers to know: Tuesday, January 5, 2016

By

Gilead's hep-C combo gets Breakthrough designation; Baxalta licences experimental cancer drugs; Novartis agrees to settle class-action lawsuit

New cardiovascular drugs raise concerns about pricing, efficacy

New cardiovascular drugs raise concerns about pricing, efficacy

By

With the huge advances in treatment comes a raft of concerns, among them daunting pricing pressures.

Five things for pharma marketers to know: Friday, December 18, 2015

Five things for pharma marketers to know: Friday, December 18, 2015

By

GlaxoSmithKline buys Bristol-Myers Squibb's research assets; Gilead Sciences makes large stake in experimental rheumatoid arthritis drug; Avandia's REMS program ends

Lantus competitor receives FDA approval

Lantus competitor receives FDA approval

By

Eli Lilly and Boehringer Ingelheim received approval to begin selling their Lantus knock-off drug after settling a patent lawsuit with Sanofi in September.

FDA advisory panel recommends Teva asthma antibody

FDA advisory panel recommends Teva asthma antibody

By

An FDA advisory committee voted 11-3, recommending approval of reslizumab in adults with severe asthma.

Five things for pharma marketers to know: Monday, December 7, 2015

Five things for pharma marketers to know: Monday, December 7, 2015

By

Gleevec generic is approved; FDA issues warning on diabetes drugs; Senate will hold hearing on drug pricing

GSK will enlist inhaler sensor to improve clinical trials

GSK will enlist inhaler sensor to improve clinical trials

By

GlaxoSmithKline announced that it signed a development agreement with Propeller Health to use its sensors in clinical trials.

Five things for pharma marketers to know: Monday, November 30, 2015

Five things for pharma marketers to know: Monday, November 30, 2015

By

Opdivo's new melanoma indication denied; Novartis weighs sale of contact lens portfolio; Sanofi prepares to sell Merial

The Pipeline Report 2016: Big-Time Upside

The Pipeline Report 2016: Big-Time Upside

By

A peek at 159 aspiring agents, with profiles on 17 that could shoot to stardom. Rebecca Mayer Knutsen has the forecast

Five things for pharma marketers to know: Tuesday, November 17, 2015

Five things for pharma marketers to know: Tuesday, November 17, 2015

By

Addyi off to a slow start; Dr. Robert Califf faces Senate committee on FDA nomination; FDA grants Opdivo Breakthrough Therapy Designation in kidney cancer

Five things for pharma marketers to know: Monday, November 16, 2015

Five things for pharma marketers to know: Monday, November 16, 2015

By

PBMs crack down on specialty pharmacies; Merck's cholesterol drug soldiers on; rare-disease drug nabs approval

Six things for pharma marketers to know: Friday, November 13, 2015

Six things for pharma marketers to know: Friday, November 13, 2015

By

Harvoni's label is expanded; AstraZeneca lung-cancer drug receives accelerated approval; Mylan's Perrigo takeover falls short

Five things for pharma marketers to know: Thursday, November 12, 2015

Five things for pharma marketers to know: Thursday, November 12, 2015

By

Not-for-profit ranks Gilead Sciences and Sanofi as the lowest-scoring drugmakers in terms of clinical trial transparency; Perrigo shareholders to vote on Mylan deal; new Valeant allegations

Pharma CEOs defend R&D model to investors

Pharma CEOs defend R&D model to investors

By

Executives at Eli Lilly, Merck and Biogen used the most recent earnings season to promote innovation and defend drug pricing.

Five things for pharma marketers to know: Tuesday, November 3, 2015

Five things for pharma marketers to know: Tuesday, November 3, 2015

By

GSK partners with other drugmakers to bolster pipeline; Pfizer makes deal in South Africa for Prevnar 13; the FDA issues guidance on HIV biologic development

Five things for pharma marketers to know: Wednesday, October 28, 2015

Five things for pharma marketers to know: Wednesday, October 28, 2015

By

Walgreens buys Rite Aid in $9.4 billion deal; Arena fires a third of its workforce and discontinues Belviq clinical trials; FDA approves Amgen melanoma immunotherapy

Diagnostics at the center of lung-cancer drug clash

Diagnostics at the center of lung-cancer drug clash

By

Oncologist perception of diagnostics may grow as immuno-oncology treatments move toward first-line use, drugmaker execs say.

Five things for pharma marketers to know: Monday, October 26, 2015

Five things for pharma marketers to know: Monday, October 26, 2015

By

FDA panel recommends AZ gout drug for approval; Valeant to form committee to examine specialty pharmacy ties; patients treated with Keytruda had longer survival than those who took chemo

Five things for pharma marketers to know: Tuesday, October 20, 2015

Five things for pharma marketers to know: Tuesday, October 20, 2015

By

Therapy and low-dose drugs found to aid schizophrenia patients more than just antipsychotics; Clinton calls for investigations into drug price increases; Bayer issues RFP for AOR for consumer care brands

Five things for pharma marketers to know: Monday, October 19, 2015

Five things for pharma marketers to know: Monday, October 19, 2015

By

The FDA approves Pradaxa antidote; Valeant CEO says he expects a new pricing environment in 2016; FDA denies Shire dry-eye drug

Five things for pharma marketers to know: Friday, October 16, 2015

Five things for pharma marketers to know: Friday, October 16, 2015

By

The NIH plans to fund fewer but more meaningful studies; the FDA asks for more data about AstraZeneca diabetes drug; payers continue to deny coverage for new hep.-C treatments

Email Newsletters